Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Clin Case Rep ; 5(3): 308-311, 2017 03.
Article in English | MEDLINE | ID: mdl-28265396

ABSTRACT

Fetal malformations detected through routine prenatal ultrasound examination comprise a heterogeneous group potentially associated with genetic disorders where the underlying cause is difficult to establish. We present the prenatal diagnosis of a rare X-linked myopathy involving a new VMA21 gene mutation, detected through a novel prenatal exome sequencing-based approach.

2.
Adv Clin Exp Med ; 25(3): 471-8, 2016.
Article in English | MEDLINE | ID: mdl-27629735

ABSTRACT

BACKGROUND: Although several studies in various countries have indicated that the presence of the E4 allele of the apolipoprotein-E (APOE) gene is a risk factor for ischemic cerebrovascular disease, the strength of this association still remains a matter of debate. OBJECTIVES: The aim of the study was to determine the frequency of the APOE E4 allele and various other gene polymorphisms in in a well-characterized sample of Greek patients and to evaluate the potential associations with the risk of ischemic stroke (IS) and coronary heart disease (CHD). MATERIAL AND METHODS: A total of nine gene variants/polymorphisms - F5 (Leiden - R5 06Q, rs6025), F2 (20210G > A, rs1799963), F13A1 (V34L, rs5985), MTHFR (677C > T - A222V, rs1801133), MTHFR (1298A > C - E429A, rs1801131), FGB (-455G > A -c.-463G > A; rs1800790), SERPINE1 (PAI14G/5G - rs1799889), ACE (ACE I/D, rs1799752), ITGB3 (GPIIIa L33P, rs5918) and the APOE E2/E3/E4 alleles (rs7412, rs429358) - were genotyped in 200 newly diagnosed ischemic stroke (IS) patients, 165 patients with ischemic coronary heart disease (CHD) and 159 controls with no cerebroor cardiovascular disease (non-CVD). A statistical analysis was performed using univariate and multivariate logistic regression models. RESULTS: No significant association was found regarding most gene polymorphisms and the presence of IS or CHD in the patient cohort. However, the APOE E4 allele frequency was significantly higher (p = 0.02) among patients with ischemic stroke (IS) or IS + CHD (12.7%) when compared to the controls (5.1%). More accurately, E4 carriers had 2.66 and 2.71 times greater likelihood of IS or IS + CHD than non-carriers, respectively (OR = 2.66, 95% CI 1.39-5.07, OR = 2.71, 95% CI 0.98-7.48). CONCLUSIONS: In contrast to some previous studies, these results support the role of the APOE E4 allele as an independent risk factor for ischemic stroke and ischemic coronary heart disease among Greek patients.


Subject(s)
Apolipoproteins E/genetics , Genetic Predisposition to Disease/genetics , Heterozygote , Stroke/genetics , Aged , Alleles , Analysis of Variance , Coronary Disease/etiology , Coronary Disease/genetics , Female , Gene Frequency , Genotype , Greece , Humans , Ischemia/complications , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Risk Factors , Stroke/etiology
3.
Hematology ; 19(4): 217-24, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23928116

ABSTRACT

OBJECTIVE: The presence of numerical and/or structural chromosomal abnormalities is a frequent finding in clonal hematopoietic malignant disease, typically diagnosed through routine karyotyping and/or fluorescent in situ hybridization (FISH) analysis. Recently, the application of array comparative genomic hybridization (aCGH) has uncovered many new cryptic genomic copy number imbalances, most of which are now recognized as clinically useful markers of haematological malignancies. In view of the limitations of both FISH and aCGH techniques, in terms of their routine application as a first line screening test, we designed a new multiple ligation-dependent probe amplification (MLPA) probemix for use in addition to classic karyotype analysis. METHODS: A novel MLPA probemix was developed to interrogate copy number changes involving chromosomal regions: 2p23-24 (MYCN, ALK), 5q32-34 (MIR145A, EBF1, MIR146A), 6q21-27, 7p12.2 (IKZF1), 7q21-36, 8q24.21 (MYC), 9p24 (JAK2 V617F point mutation), 9p21.3 (CDKN2A/2B), 9p13.2 (PAX5), 10q23 (PTEN), 11q22.3 (ATM), 12p13.2 (ETV6), 13q14 (RB1, MIR15A, DLEU2, DLEU1), 17p13.1 (TP53), and 21q22.1 (RUNX1/AML1) and was applied to DNA extracted from 313 consecutive bone marrow patient samples, referred for routine karyotype analysis. RESULTS: More than half of the samples originated from newly investigated patients. We discovered clinically relevant genomic aberrations, involving a total of 24 patients (8%) all with a normal karyotype, which would have remained undiagnosed. DISCUSSION: Our data clearly indicate that routine application of this MLPA screening panel, as an adjunct to karyotype analysis, provides a sensitive, robust, rapid and low-cost approach for uncovering clinically important genomic abnormalities, which would have otherwise remained undetected.


Subject(s)
Chromosome Aberrations , Cytogenetic Analysis/methods , Gene Dosage , Hematologic Neoplasms/genetics , Cytogenetic Analysis/economics , Genomics/economics , Genomics/methods , Humans
4.
Prenat Diagn ; 31(6): 571-7, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21448863

ABSTRACT

OBJECTIVE: To present the application of multiplex ligation-dependent probe amplification (MLPA)-based screening approach in 1550 typical prenatal cases, for the simultaneous targeted detection of 23 recurrent microdeletion syndromes as well as subtelomeric copy number assessment for all chromosomes and discuss the implications in routine prenatal chromosomal diagnosis (PCD). METHODS: Following amniocentesis or chorionic villus sampling, samples were processed for routine karyotype analysis while DNA was extracted in parallel for MLPA analysis. When necessary, parental samples were analyzed to determine the inheritance of the detected aberrations. RESULTS: This panel has been applied since 2006 in 1550 prenatal samples, referred for routine karyotype analysis, with (16.1%) or without (77.7%) ultrasound (US) findings. We identified eight fetuses with pathological genomic abnormalities (approximately 1 in 193), five of which had as sole indication advanced maternal age (1 in 240). In two cases an abnormality was suspected from karyotype analysis, while the remaining six cases would have otherwise remained totally undetected. CONCLUSIONS: Our data represent the largest published series involving this type of genomic analysis in routine prenatal diagnosis, without indication bias. The panel increases significantly the diagnostic yield of conventional PCD and does not pose interpretation problems.


Subject(s)
Chromosome Deletion , Diagnostic Tests, Routine/methods , Gene Duplication , Nucleic Acid Amplification Techniques/methods , Prenatal Diagnosis/methods , Adult , Chorionic Villi Sampling/statistics & numerical data , Chromosome Aberrations/statistics & numerical data , Comparative Genomic Hybridization , Diagnostic Tests, Routine/statistics & numerical data , Female , Humans , Incidence , Karyotyping , Male , Pregnancy , Prenatal Diagnosis/statistics & numerical data , Recurrence , Syndrome , Telomere/genetics
5.
Fetal Diagn Ther ; 22(1): 41-4, 2007.
Article in English | MEDLINE | ID: mdl-17003555

ABSTRACT

OBJECTIVE: The implementation and evaluation of a proposed wide-scale prenatal screening strategy, based on DNA isolated from dried blood spots in the first trimester of pregnancy, for the early detection of pregnancies at risk for cystic fibrosis (CF). METHODS: The screening was performed in conjunction with routine biochemical marker screening for Down's syndrome risk in the first trimester of pregnancy. DNA was isolated from 1,233 dried blood spots and analyzed for the presence of the CF transmembrane regulator DeltaF508 mutation. Women carriers were offered and accepted the option for additional full testing of their partners in order to assess the risk for the fetus. RESULTS: All 1,233 samples were successfully analyzed, identifying 23 DeltaF508 carriers, corresponding to a DeltaF508 carrier rate of approximately 1/55 (1.8%). All partners of the women carriers were further tested without revealing any need for further prenatal testing in this group. CONCLUSIONS: This study reveals the relatively high frequency of the DeltaF508 CF mutation in the Greek population. More importantly, we demonstrate that the proposed prenatal screening strategy, based on the ease and cost-effectiveness of the analysis for the detection of a single common mutation, can be considered as a feasible and practical approach for wide-scale prenatal screening for CF, following the sequential model. It is applied early on in pregnancy, allowing for the timely management of families at risk for the corresponding genetic disorders. Finally, it can easily be extended to include screening for other common genetic disorders in specific population groups.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/diagnosis , Genetic Testing/methods , Prenatal Diagnosis/methods , Cystic Fibrosis/epidemiology , Cystic Fibrosis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/blood , Female , Greece/epidemiology , Humans , Male , Mutation , Pilot Projects , Pregnancy , Pregnancy Trimester, First , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...